人葡萄球菌血流感染耐药及预后分析被引量：1

导出

摘要目的了解人葡萄球菌血流感染的临床特点及菌株耐药情况。方法回顾性分析安徽医科大学第一附属医院2008~2015年人葡萄球菌血流感染的101例患者临床资料、实验室检查结果及菌株耐药情况。结果 95例(94.1%)患者存在基础疾病,79例(78.2%)存在免疫缺陷,49例(48.5%)有长期留置导管。好转74例(73.3%),非好转27例(26.7%);人葡萄球菌血流感染合并恶性肿瘤、不恰当用药是影响患者预后的危险因素(P<0.05)。人葡萄球菌对红霉素、苯唑西林、四环素及复方新诺明耐药率分别是91.1%、78.2%、58.5%和55.4%,万古霉素、喹努普汀/达福普汀、利奈唑胺耐药率低。结论不恰当用药、合并恶性肿瘤为影响人葡萄球菌血流感染预后的危险因素,人葡萄球菌耐药率高。

作者邓洋李家斌

机构地区安徽医科大学第一附属医院感染科

出处《安徽医学》 2017年第6期735-738,共4页 Anhui Medical Journal

基金安徽省自然科学基金(项目编号:1408085QH176)

关键词人葡萄球菌血流感染耐药性预后分析

分类号 R515 [医药卫生—内科学]

引文网络
相关文献

参考文献3

1郭燕,朱德妹,胡付品,汪复,俞云松,杨青,张泓,孔菁,王传清,王爱敏,胡云建,艾效曼,孙自镛,陈中举,倪语星,孙景勇,徐元宏,沈继录,单斌,杜艳,张朝霞,季萍,徐英春,孙宏莉,魏莲花,吴玲,苏丹虹,卓超,贾蓓,黄文祥.2010年中国CHINET葡萄球菌属细菌耐药性监测和分析[J].中国感染与化疗杂志,2013,13(2):86-92. 被引量：53
2医院感染诊断标准(试行)[J].中华医学杂志,2001,81(5):314-320. 被引量：6449
3黄延玲,张素真,黄群,马红,林志青.利奈唑胺和万古霉素对革兰阳性球菌感染治疗效果的Meta分析[J].中国抗生素杂志,2012,37(7):545-557. 被引量：38

二级参考文献74

1Fluckiger U, Widmer A F. Epidemiology of methicillin- resistant Staphylococcus aureus[J]. Chemotherapy, 1999, 45(2): 121-134.
2Jones R N, Low D E, Pfaller M A. Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant Gram-positive bacteria: The role of streptogramins and other newer compounds[J]. Diagn Microbiol lnfect Dis, 1999, 33(2): 101-112.
3Herold B C, Immergluck L C, Maranan M C, et al. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk[J]. JAMA, 1998, 279(8): 593-598.
4Richards M J, Edwards J R, Culver D H, et al. Nosocomial infections in combined medical-surgical intensive care anits in the United States[J]. Infect Control Hosp Epidemiol, 2000, 21(8): 510-515.
5Vincent J L, Bihari D J, Surer P M, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee[J]. JAMA, 1995, 274(8): 639-644.
6Fridkin S K, Hill H A, Volkova N V, et al. Temporal changes in prevalence of antimicrobial resistance in 23 US hospitals[J]. Emerg Infect Dis, 2002, 8(7): 697-701.
7Carbon C. Costs of treating infections caused by methicillin- resistant staphylococci and vancomycin-resistant enterococci[J]. JAntimicrob Chemother, 1999, 44 (suppl A): 31-36.
8Engemann J J, Carmeli Y, Cosgrove S E, et al. Adverseclinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection[J]. Clin Infect Dis, 2003, 36(5): 592-598.
9Hiramatsu K, Hanaki H, Ino T, et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility[J]. J Antimicrob Chemother, 1997, 40(1): 135-136.
10Centers for Disease Control and Prevention(CDC). Reduced susceptibility of Staphylococcus aureus to vancomycin- Japan, 1996. MMWR Morb Mortal Wkly Rep, 1997, 46(27): 624-626.